United States Patent 6,432,948 (Drug Patent): Scope, Claims, and US Landscape for Helicobacter pylori Treatment
What does US 6,432,948 claim in plain scope terms?
US Patent 6,432,948 is centered on anti-Helicobacter pylori and Helicobacter-associated gastroduodenal disorder treatment using defined quinoline-carboxylic acid derivatives (and stereochemically purified exemplars), with coverage structured around:
- A Markush-style compound genus (Formula (I)) that is administered to treat H. pylori infection and/or gastroduodenal disorder associated with H. pylori (Claims 1–3).
- Explicit stereochemical variants of the genus (Claims 4–7): racemate, diastereomer mixture, purified enantiomer, purified diastereomer.
- A narrower, enumerated set of diastereomerically pure and enantiomerically pure specific compounds (Claim 8) that also supports method and composition coverage (Claims 9–10).
The claims are method-of-treatment claims first, with composition coverage tied directly to the stereochemically pure compound(s) of Claim 8.
What is the claim “spine” of the patent (independent claim coverage)?
Claim 1 (Independent method-of-treatment over Formula (I))
Claim 1 covers:
- Patient population/purpose: “a patient” with
(i) Helicobacter pylori infection and/or (ii) gastroduodenal disorder associated with a Helicobacter pylori infection
- Therapeutic act: administering an effective amount
- Drug substance: at least one compound of Formula (I) with substituent limits defined by:
- R1: alkyl (C1 to C4) optionally halogenated; or phenyl optionally difluorinated; or cyclopropyl optionally difluorinated
- R2: H, C1 to C4 alkyl optionally substituted (hydroxyl, methoxy, amino, methylamino, dimethylamino), or (5-methyl-2-oxo-1,3-dioxol-4-yl)-methyl
- A: “N or C-R3”
- R3: H, halogen, methyl, methoxy, difluoromethoxy, cyano
- and/or forms a bridge with R1 through a defined linkage motif:
—O—CH2—CH—CH3 or —O—CH2—N—CH3
- R4: H, benzyl, C1 to C3-alkyl, (5-methyl-2-oxo-1,3-dioxol-4-yl)-methyl, or defined acyl/alkyl fragments including:
- —CH═CH—COOR5; —CH2—CH2COOR5; —CH2—CH2CN; —CH2—CH2COCH3; —CH2—COCH3
- where R5 = methyl or ethyl
- R6: H, amino, hydroxyl, methyl, or halogen
- Coverage includes pharmaceutically utilizable hydrates and/or salts of the compounds
Practical interpretation: Claim 1 is broad on the therapeutic use and medium-to-wide on chemical genus via Formula (I), but it is not “anything that treats H. pylori.” It is limited to quinoline-carboxylic acid derivatives constrained by R-group permutations and the A/R1 “bridge” geometry.
Claim 10 (Independent method-of-treatment over Claim 8 compounds)
Claim 10 is another method-of-treatment, but constrained to the specific stereochemically pure enumerated compounds of Claim 8.
Claim 9 (Composition claim tethered to Claim 8)
Claim 9 covers a pharmaceutical composition containing at least one compound according to Claim 8 plus a pharmaceutically utilizable carrier.
Practical interpretation: The composition claim is narrow by design: it does not cover Formula (I) broadly, only the Claim 8 purified stereoisomer set.
How do dependent claims narrow or expand the chemical scope?
Claims 2–3 (Dependent genus narrowing by selecting R1/R2/A/R4/R6 sets)
These claims keep the Formula (I) framework but impose tighter enumerations of substituent possibilities.
Practical interpretation: Claims 2 and 3 create “corridor” coverage within Claim 1 that is easier to map to specific marketing candidates.
Claims 4–7 (Stereochemical claim branching)
These claims address stereochemical mixtures and purified forms:
- Claim 4: racemic mixture of Formula (I), or hydrate/salt
- Claim 5: diastereomer mixture of Formula (I), or hydrate/salt
- Claim 6: purified enantiomer of Formula (I), or hydrate/salt
- Claim 7: purified diastereomer of Formula (I), or hydrate/salt
Practical interpretation: These claims reduce design-around space by covering how the genus is presented stereochemically.
Claim 8 (Enumerated stereochemically pure compounds)
Claim 8 identifies a closed set of diastereomerically pure and enantiomerically pure compounds:
- 8-cyano-1-cyclopropyl-6-fluoro-7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
- 1-cyclopropyl-8-difluoromethoxy-6-fluoro-1,4-dihydro-7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-4-oxo-3-quinolinecarboxylic acid
It also covers pharmaceutically utilizable hydrates and/or salts of those compounds.
Practical interpretation: Claim 8 is the “needle” claim. It is not a Markush open ended set. It is a defined list of purified stereoisomer targets.
What is the legal/technical “attack surface” for competitors (where design-arounds typically occur)?
Based on the structure of claims, competitors face three primary freedom-to-operate fault lines:
1) Therapeutic intent and method-of-treatment framing
Coverage is explicitly method for treating H. pylori infection and/or H. pylori-associated gastroduodenal disorder, with administration of an effective amount.
- If a competitor pursues a different indication or does not practice a treatment method in the US, that affects infringement posture (though statutory and regulatory realities often still bring generic “labeling” into play).
2) Chemical genus boundary of Formula (I)
Claim 1’s scope depends on:
- permitted values for R1/R2/A/R3/R4/R5/R6
- whether A/R1 satisfies the bridge formation rules
- whether R4 includes specific fragment sets (including multiple carbonyl/ester/amide-like and cyano-containing substituent classes)
A design-around typically targets:
- switching R4 to a substituent not listed
- removing cyano/difluoromethoxy motifs
- altering the allowed “bridge” topology that links A with R1
- selecting R6 outside permitted heteroatoms/substitution states
3) Stereochemical choices
Even if a compound sits within the chemical genus, Claims 4–7 and Claim 8 narrow the stereochemical embodiment.
- A competitor would need to ensure the commercial compound is not “purified enantiomer/diastereomer” within Claim 6/7 scope, but Claim 4/5 already pick up racemate/diastereomer mixtures.
- The strongest constraint is Claim 8 because it enumerates diastereomerically pure and enantiomerically pure compounds by name and structure. If a competitor’s API matches those exact stereochemical entities, the shield is direct.
What does this imply for the US patent landscape around 6,432,948 (strategic view)?
Without using additional documents beyond the claim text provided, the landscape can be mapped at a structural level:
Layer 1: Genus coverage (Claims 1–3)
- Breadth is driven by Formula (I) variable sets.
- Dependent claims 2 and 3 narrow toward specific R-group selections, likely closer to exemplified leads.
Layer 2: Stereochemistry coverage (Claims 4–7)
- Broadens practical infringement probability by covering how the genus is sold (racemate vs. stereopure).
Layer 3: Enumerated stereopure API coverage (Claim 8)
- Concentrates enforceability on two specific diastereomerically and enantiomerically pure acids (and hydrates/salts).
- Also drives a composition claim (Claim 9) and additional method coverage (Claim 10).
Layer 4: Drug product planning and formulation
- Because Claim 9 is tied to Claim 8 compounds, the product strategy matters: a competitor who chooses a different stereochemical set might avoid Claim 9 composition infringement even if Claim 1 method-of-treatment remains in play.
Claim-by-claim scope map (structured checklist)
| Claim |
Type |
Chemical scope |
Indication scope |
Key “must match” elements |
| 1 |
Method |
Formula (I) genus via R1/R2/A/R3/R4/R6 |
H. pylori infection and/or H. pylori-associated gastroduodenal disorder |
Effective amount; Formula (I) variable constraints; bridge motif rules; salts/hydrates included |
| 2 |
Method |
Narrowed Formula (I): R1 tert-butyl or cyclopropyl; restricted R2/A/R4/R6 sets |
Same as Claim 1 |
Same as Claim 1 plus dependent restrictions |
| 3 |
Method |
Further narrowed Formula (I): R2 H/methyl/ethyl; R4 H/methyl; R6 H; restricted R1/A |
Same |
Same as Claim 1 plus dependent restrictions |
| 4 |
Method |
Formula (I) racemate |
Same |
Stereochemical embodiment (racemic mixture); salts/hydrates allowed |
| 5 |
Method |
Formula (I) diastereomer mixture |
Same |
Stereochemical embodiment (diastereomer mixture); salts/hydrates allowed |
| 6 |
Method |
Formula (I) purified enantiomer |
Same |
Enantiomerically purified embodiment; salts/hydrates allowed |
| 7 |
Method |
Formula (I) purified diastereomer |
Same |
Diastereomerically purified embodiment; salts/hydrates allowed |
| 8 |
Substance definition |
Enumerated stereopure acids (2 named structures) |
Not separately stated (defines drug) |
Exact enumerated stereochemistry; hydrates/salts |
| 9 |
Composition |
At least one Claim 8 compound |
Not separately stated |
Carrier + Claim 8 compound(s) |
| 10 |
Method |
At least one Claim 8 compound |
H. pylori infection and/or H. pylori-associated gastroduodenal disorder |
Effective amount; Claim 8 compound match |
What practical conclusions can be drawn for R&D and licensing?
1) Two-compound “anchor” likely drives enforceability
Claim 8 provides a defined list of stereopure APIs with tight chemical identifiers. In licensing and diligence, the decisive question is whether a candidate API matches those exact stereochemical structures (including salts and hydrates).
2) Genus claims prevent easy “swap to another R-group” unless outside Formula (I)
Claims 1–3 constrain multiple substituents and topology rules. A competitor can still design around by selecting substituents outside the listed sets, but the bridge rule and R4 fragment set are common points of structural sensitivity.
3) Stereochemistry is not a safe harbor
Claims 4–7 cover racemate, diastereomer mixtures, and purified stereochemical forms. That makes stereochemical re-positioning less effective unless the competitor exits the Formula (I) boundary entirely or avoids matching Claim 8 stereopure entities.
Key Takeaways
- US 6,432,948 is a H. pylori treatment patent built around Formula (I) quinoline-carboxylic acids with constrained R-group permutations and an A/R1 bridge motif.
- Claims 1–3 cover method-of-treatment using the genus; Claims 4–7 cover stereochemical embodiments (racemate, diastereomer mixtures, purified enantiomers, purified diastereomers).
- Claim 8 is the enforceability anchor: it enumerates two specific diastereomerically and enantiomerically pure compounds, and it directly enables:
- Claim 9 composition coverage (API in a carrier), and
- Claim 10 method coverage for the same two APIs.
- A credible design-around must address both: (i) leaving the Formula (I) variable constraints and topology, and (ii) avoiding the exact Claim 8 stereochemically pure targets.
FAQs
1) Does the patent cover compositions for any Formula (I) compound?
No. Claim 9 is limited to compounds of Claim 8 plus a pharmaceutically utilizable carrier.
2) Can a competitor avoid infringement by selling a racemate instead of a purified enantiomer?
Not automatically. Claim 4 covers the racemic mixture of Formula (I), and Claims 5–7 cover diastereomer mixtures and purified stereochemical forms.
3) What is the key difference between Claim 1 and Claim 10?
Claim 1 covers method-of-treatment using the broad Formula (I) genus. Claim 10 restricts the drug substance to the enumerated Claim 8 stereopure compounds.
4) What structural themes are most likely to matter for validity and infringement mapping?
The permitted sets for R1/R2/A/R3/R4/R6, the bridge formation rule between A and R1, and the inclusion/exclusion of specific R4 fragment classes.
5) How does Claim 8 change the patent landscape compared with the Markush genus?
Claim 8 is a closed list of two stereochemically pure compounds. It creates direct coverage for those exact APIs, including their hydrates and salts, and it supports both composition and method claims tied to those compounds.
References
[1] United States Patent US 6,432,948, claims as provided in user prompt (Claims 1–10).
